Our CMO Julie Gralow discusses #ASCOQLTY25 research being presented now highlighting the importance of federal funding in cancer #ClinicalTrials—particularly early phase, dose de-escalation, rare cancer, multimodality, and child-focused Tx trials. brnw.ch/21wWxJt #pedcsm

💫 The stars align at #ESMO25! The #NorthStar trial evaluates osimertinib ± local consolidative therapy in EGFR-mutant metastatic NSCLC. A study that could illuminate the next step in precision oncology — we’re watching closely! 🌌 OncoAlert #LungCancer #ESMO25

#ESMO25 Dr. Edurne Arriola Aperribay will present 1817MO on MRD in the LAURA trial (consolidation osimertinib after CRT for stage III EGFR NSCLC). At baseline, 57% were MRD+, 84% cleared, MRD with no impact on PFS. Molecular PD preceded radiographic PD by 5.1m. #ESMOAmbassadors

𝗧𝗢𝗗𝗔𝗬: ISN Renal Pathology Working Group webinar: "Update on monoclonal gammopathy of renal significance." 🗣️ Lihong Bu, Pouneh Dokouhaki, Manoj Jain, Turki Al Hussain 👤 Carmen Avila, Fred Maate 🗓️ October 14 🕓 2 pm CEST 🔗 Free registration: lite.spr.ly/6004MEEs

New Research: Notch signalling in T cells: bridging tumour immunity and intratumoral cellular crosstalk frontiersin.org/articles/10.33… #FrontiersIn #Immunology

1/2 As #EmergencyMedicine Doctors Become #Indemnity Sponges Will Their MPS/MDU #Subscriptions ⬆️ ? Ian Higginson Chris Moulton Adrian Boyle Salwa Malik Jeanette Dickson The BMA BMA SAS Doctors Resident Doctors Medical Protection The MDU MDDUS The Lawyer FFLM

#ESMO25 ALINA: Adjuvant alectinib vs chemo in resected ALK+ NSCLC 🔹 ~4-year follow-up 🔹 DFS: HR 0.35–0.36, 4y rate 75% vs 47% 🔹 CNS-DFS: HR 0.37 🔹 OS immature 💬 Long-term data confirm adjuvant alectinib as standard of care in resected ALK+ NSCLC

🚨 New in EJC: genomic insights from a multinational cohort of BTC treated with CisGem+D! ejcancer.com/article/S0959-… 🧬 HRD/BRCA alterations → ↑OS (23.3 vs 13.8m) & PFS (13.2 vs 8.1m) ▪️ TGF-β pathway → longer PFS (16 vs 8.1m) ⬆️ High TMB (>10 mut/Mb) → best outcomes 💥 When

Pleased to share that the paperback version of the proceedings of the most recent international WIN Consortium Symposium in collaboration with Advancing Precision Medicine is now available on Amazon 2025 WIN SYMPOSIUM: PROGRESS AND CHALLENGES IN PRECISION ONCOLOGY a.co/d/hr1di0w

#GiuseppeCatanuto on #UEMS in Surgical Oncology awareness and perception: organ-based or surgical oncology first? UEMS OncoAlert #ESSO44

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Anders Thornell 🇸🇪 Sahlgrenska Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated? Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and

Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas - The Lancet Haematology thelancet.com/journals/lanha…

📹 WATCH: Dr Colette Shen UNC Lineberger discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and neck cancer #HNSCC. #radiotherapy hubs.li/Q03Nrn8m0

From regulatory designations for promising new drugs, to crucial clinical trials, review the latest developments in oncology, in Targeted Oncology's weekly roundup: bit.ly/46OVOMe #ClinicalTrial #FDAApprovals #CancerResearch

Immunotherapy researcher Miriam Merad from Icahn Mount Sinai says the reason that cancer research has slowed is because of funding issues, which is something taxpayers don’t have to accept. “We fight for patients, we fight for science, and we have to fight for progress.”

🌍 Read testimonials from a #GlobalCommunity of #oncologists who have grown through ESMO. 📸 Now it is your turn to be a part of it: share a photo and tell us about your experience with #myESMOStory. #ESMO25. 🔗ow.ly/H58950XceSs

The next #IACwebinar for #IACmembers is approaching: 20 Nov at 13:00 CET (07:00 EDT). The topic: Liquid Biopsy & #Cytopath: The Perfect Marriage by Prof. Umberto Malapelle. Preregister now here: cytology-iac.org/members-area/i…

📣 Don’t miss! #ESMO25 Mini Oral – Sarcoma (16:00 CEST) 1️⃣ BIOVAS: VEGFR2 inhib. in biomarker-sel. sarcoma 2️⃣ CONgRAtS: Nivo ± Relatlimab in TLS+ STS 3️⃣ FOG-001: β-catenin:TCF4 inhib. in desmoid tumors 4️⃣ MANEUVER: Pimicotinib in TGCT 5️⃣ BFR14: 20-yr f/u of GIST w/ imatinib…

📢NorthStar led by Yasir Yousif Elamin & MD Anderson Cancer Center Team just out at #ESMO25 Addition of local therapy (#radiotherapy or/and surgery) prolongs mPFS in #EGFR mutant #lungcancer 🔥Important trial🔥 Looking forward to discussion by Zosia Piotrowska My quick take below👇🙏OncoAlert

For everyone attending #ESMO25: do not miss history in the making with the first ever Tumor-Agnostic Track! So proud to see my wife Juliana Beal, MD co-chair the Saturday’s Special Symposium “Tumour-agnostic anticancer therapies: Ready for prime time?” Vivek Subbiah, MD Jia (Jenny) Liu MD PhD